Navigation Links
Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
Date:2/3/2009

HOPKINTON, Mass., Feb. 3 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE), announced today that it has completed enrollment in the first stage of the Altropane Parkinson's or Essential Tremor (POET-2) Phase III clinical program. The objective of the first part of the program was to acquire the set of Altropane images which will be used to train expert readers for the Phase III registration portion of the program. The Altropane molecular imaging agent is being developed by Alseres to aid in the early diagnosis of Parkinsonian Syndromes (PS).

(Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO )

There are 11 million people in the U.S. alone living with tremor disorders of which more than one million have been diagnosed with Parkinson's disease. These figures are expected to double by 2030. According to peer-reviewed publications, misdiagnosis rates for PS are reported as high as 35-50%. "Millions of people experiencing tremor symptoms currently have no objective means to determine whether or not they have Parkinson's Disease," Ray L. Watts, MD, John N. Whitaker Professor and Chairman of the Department of Neurology, University of Alabama at Birmingham stated. "There is a clear need to improve the process for earlier diagnosis of Parkinson's Disease which improves patient outcomes and their ability to take advantage of neuroprotective therapies as they become avai
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
2. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
3. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
4. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
5. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
6. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
7. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... CHESTER, Pa. , Sept. 19, 2014 /PRNewswire/ ... launched two new variable angle plating systems featuring ... technology, surgeons can adapt screw trajectory to match ... towards specific fragments of bone. The systems are ... Foot & Ankle Society (AOFAS) and the International ...
(Date:9/19/2014)... , Sept. 19, 2014 /PRNewswire-iReach/ -- ... to 2020″, provides key market data ... devices market. The report provides value, ... volume (in units) within market categories ... Sigmoidoscopes, Esophagoscopes & Gastroscopes, Duodenoscopes, Laparoscopes, ...
(Date:9/19/2014)... TRIANGLE PARK, N.C. , Sept. 19, 2014 ... focused on cloud-based drug design and development, partnering ... The company,s mission is to design new drugs ... 1 and 2 partners to further their development. ... its portfolio investments. To support this business model, ...
Breaking Medicine Technology:DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2
... N.J., June 8, 2011 Amerigen Pharmaceuticals Limited ... into a broad-based collaboration agreement regarding the development ... terms of the agreement, AustarPharma will use its ... Amerigen to commercialize in the United States and ...
... ATLANTA, June 8, 2011 Elekta has collaborated with ... NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ... offers Elekta users real-time access to NCCN,s evidence-based clinical ... " The NCCN Guidelines ...
Cached Medicine Technology:Amerigen Pharmaceuticals and AustarPharma Enter Into Collaboration Agreement for Generic Oral Controlled Release Products 2National Comprehensive Cancer Network Guidelines Available in Elekta's MOSAIQ EMR 2
(Date:9/22/2014)... Mississauga, Ontario (PRWEB) September 22, 2014 ... August 1st, 2014 at the PWN International Conference in ... Canadian release that was celebrated with a reception attended ... this reception Dawn shared insights she had gained while ... organizational side of the glass ceiling issue, and what ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Fancyflyingfox.com, the well-known ... collection of 2014 plus size wedding dresses . In ... offer for these fashionable plus size outfits. Each item in ... price, up to 65% off. , The company has ... of them are now available at extremely affordable prices. Its ...
(Date:9/21/2014)... September 22, 2014 CareSpan USA, Inc. ... entered into a joint services agreement with Avera eCARE, ... deploy the CareSpan Virtual Clinic in multiple states where ... plan to deploy their joint services in remote and ... where Avera eCARE is licensed. The two companies’ strategy ...
(Date:9/21/2014)... study of cancer patients who smoke, those using e-cigarettes ... and equally or less likely to have quit smoking ... Cancer , a peer-reviewed journal of the American Cancer ... of e-cigarettes for helping cancer patients give up smoking. ... cancer patients who smoke should be advised to quit. ...
(Date:9/21/2014)... of the leading online stores of real and synthetic hair ... human hair lace wigs inspired by 6 famous celebrities. It’s ... latest celebrity hairstyles are. , For people who ... to choose from: a style of yaki straight lace wig, ... ombre red lace wig. People can go to the product ...
Breaking Medicine News(10 mins):Health News:Ruby Report Book Launch Reveals Critical Insights on Gender Intelligence 2Health News:Discounted Plus Size Wedding Dresses Available At Fancyflyingfox.com 2Health News:Avera eCARE and CareSpan form Collaboration to Deliver “Virtualized” Primary Care in the Dakotas and Wyoming 2Health News:Avera eCARE and CareSpan form Collaboration to Deliver “Virtualized” Primary Care in the Dakotas and Wyoming 3Health News:E-cigarettes unhelpful in smoking cessation among cancer patients 2Health News:UniWigs New Arrivals Just In- Human Hair Lace Wigs Inspired By Famous Celebrities 2
... Guttmacher,Institute,s latest report on world abortion rates is ... W. Mosher. The,study, just released today, argues that ... developing countries., Accurate numbers are impossible to ... illegal. Says Mosher: "Neither,Guttmacher nor anyone else knows ...
... Breast Cancer Awareness Month, Premier Partnerships,Promote Breast ... breastcancer.org today,announced several "pink" corporate and retail ... Awareness month in October.,Corporate sponsorships include Campbell ... Baking Company with new retail,partnerships ranging from ...
... VIRGINIA BEACH, Va., Oct. 10 AMERIGROUP,Corporation (NYSE: ... report its earnings,for the third quarter ended September ... 24, 2007. At 9:30 a.m. Eastern Time on ... conference call and webcast,to discuss earnings and other ...
... standard chemo targets HER2-positive tumors , , WEDNESDAY, Oct. 10 ... the drug paclitaxel (Taxol) cuts the recurrence of breast ... form of tumor, a new study finds. , Those ... excess of the protein human epidermal growth factor receptor-2 ...
... Ind. - While biometric equipment is gaining popularity in ... to buildings, industries are finding that many users believe ... germs that could cause illness. , But a Purdue ... surfaces of devices that scan fingerprints or hand geometry ...
... NEW YORK, Oct. 10 The "perfect storm" in ... the incidence of Chronic,Fatigue Syndrome (CFS) and Fibromyalgia (FMS) ... five separate studies. The numbers for those with,CFS in ... re-tallied,at closer to 2.5 million. Previous estimates placed the ...
Cached Medicine News:Health News:PRI Criticizes Guttmacher Report 2Health News:Nationally Recognized Corporations and Retailers Rally Behind breastcancer.org 2Health News:Nationally Recognized Corporations and Retailers Rally Behind breastcancer.org 3Health News:AMERIGROUP Corporation to Discuss Third Quarter Earnings on October 25 2Health News:Drug a New Weapon Against One Form of Breast Cancer 2Health News:Drug a New Weapon Against One Form of Breast Cancer 3Health News:Biometric sensors no dirtier than doorknobs, study finds 2Health News:Biometric sensors no dirtier than doorknobs, study finds 3Health News:'From Fatigued to Fantastic!' Provides Antidote to Energy Crisis 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: